This could be achieved by inhibiting of RANK-RANKL interaction and thus RANK signaling into AML cells, e.g., using denosumab, a clinically approved neutralizing RANKL antibody that was found to improve disease-free survival in breast cancer patients [51]. Here, TNFRSF11A is linked to breast carcinoma.